SecBot SecBot
SECBOTREPLAY Home › Report › NRIX

NRIX · Nurix Therapeutics presented new preclinical data at AACR 2026 across…

Nurix Therapeutics, Inc. · PRESS-RELEASE filed Apr 22, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Apr 22, 2026 at 07:00 ET

Nurix Therapeutics presented new preclinical data at AACR 2026 across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972, highlighting deeper biological responses and synergy over existing inhibitors. The data reinforce the company's scientific leadership in targeted protein degradation but do not include clinical efficacy results. An upcoming AACR Advances session features Nurix’s CSO discussing clinical translation of degraders.

  • Presented preclinical data for NRX-0305 showing 142% increase in lifespan vs. 12% for approved BRAF inhibitor in melanoma brain metastasis model.
  • NX-1607 demonstrated single-agent anti-tumor activity and synergy with anti-PD-1 in multiple syngeneic models; early clinical data show target engagement via pHS1 modulation.
  • NRX-4972 achieved 60% survival in SCLC model vs. 0% for AURKA inhibitors alisertib and LY3295668.
  • No clinical efficacy data reported; all results are preclinical or early-phase biomarker signals.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access